Karyopharm Therapeutics Inc KPTI Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$0.05 down $0.01, 20.47% on Nov 6
Last price · Previous close $0.06
- Market cap
- At the last price
- P/E ratio
- On last 12 months’ EPS
- Diluted EPS
- Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$0.05down $0.01, 20.47%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.06Nov 5
- Volume18.85MNov 5 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume10.09MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.05 to $10.99; now $0.05
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the last price. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
KPTI trailed the S&P 500 in all 7 periods.
| Period | KPTI and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | KPTI: down 92.6% S&P 500: down 5.6% | KPTI trailed the S&P 500 by 87.0 percentage points Trailed |
| 3M | KPTI: down 97.5% S&P 500: down 4.1% | KPTI trailed the S&P 500 by 93.4 percentage points Trailed |
| YTD | KPTI: down 99.4% S&P 500: up 8.7% | KPTI trailed the S&P 500 by 108.1 percentage points Trailed |
| 1Y | KPTI: down 99.1% S&P 500: up 10.9% | KPTI trailed the S&P 500 by 110.0 percentage points Trailed |
| Long term | ||
| 3Y | KPTI: down 99.6% S&P 500: up 75.0% −84.6% vs +20.5% a year | KPTI trailed the S&P 500 by 174.6 percentage points Trailed |
| 5Y | KPTI: down 100.0% S&P 500: up 67.8% −79.3% vs +10.9% a year | KPTI trailed the S&P 500 by 167.8 percentage points Trailed |
| 10Y | KPTI: down 100.0% S&P 500: up 313.1% −53.6% vs +15.2% a year | KPTI trailed the S&P 500 by 413.1 percentage points Trailed |
$10,000 invested in KPTI 10 years ago (Nov 4, 2016) would be worth about $5 as of , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
KPTI trailed the S&P 500 in all 7 periods.
| Period | KPTI and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | KPTI: down 92.6% S&P 500: down 5.6% | KPTI trailed the S&P 500 by 87.0 percentage points Trailed |
| 3M | KPTI: down 97.5% S&P 500: down 4.3% | KPTI trailed the S&P 500 by 93.2 percentage points Trailed |
| YTD | KPTI: down 99.4% S&P 500: up 7.8% | KPTI trailed the S&P 500 by 107.2 percentage points Trailed |
| 1Y | KPTI: down 99.1% S&P 500: up 9.7% | KPTI trailed the S&P 500 by 108.8 percentage points Trailed |
| Long term | ||
| 3Y | KPTI: down 99.6% S&P 500: up 68.8% −84.6% vs +19.1% a year | KPTI trailed the S&P 500 by 168.4 percentage points Trailed |
| 5Y | KPTI: down 100.0% S&P 500: up 56.9% −79.3% vs +9.4% a year | KPTI trailed the S&P 500 by 156.9 percentage points Trailed |
| 10Y | KPTI: down 100.0% S&P 500: up 252.6% −53.6% vs +13.4% a year | KPTI trailed the S&P 500 by 352.6 percentage points Trailed |
$10,000 invested in KPTI 10 years ago (Nov 4, 2016) would be worth about $5 as of , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$706.80
Closing high on . Now 100.0% below that record.
Split-adjusted daily closes since Nov 6, 2013.
Stock splits
1
1-for-15 on . Share counts adjust after each split.
Valuation
Financials
About Karyopharm Therapeutics Inc
Karyopharm Therapeutics is a commercial-stage pharmaceutical company pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer. The Company's lead therapy, XPOVIO® (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the U.S. for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO® in more than 50 ex-U.S. countries and territories. Building on its leadership in XPO1 biology, Karyopharm is advancing selinexor's potential in hematologic cancers, including in myelofibrosis. The Company is also exploring opportunities to evaluate XPO1 inhibition across myeloproliferative neoplasms using next-generation compounds, including eltanexor. Headquartered in Newton, Massachusetts, Karyopharm has an established, efficient and scalable commercialization infrastructure to bring novel therapeutic options to patients with cancer.
- Sector
- Industry
- Headquarters
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
KPTI news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
KPTI stock FAQ
What is KPTI stock’s price today?
Karyopharm Therapeutics (KPTI) traded at $0.05 as of , down $0.01 (20.47%) from the previous close of $0.06. Over the past 52 weeks it has traded between $0.05 and $10.99.
If you invested $1,000 in KPTI 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in KPTI on would be worth about $0 as of , a total return of −100.0%. The same $1,000 would be worth $0 if invested five years ago and $9 if invested one year ago. Past performance doesn’t predict future returns.
Does KPTI pay a dividend?
Karyopharm Therapeutics hasn’t paid a dividend in the last twelve months.
What is KPTI’s 52-week high and low?
Over the past 52 weeks KPTI has traded as low as $0.05 and as high as $10.99. At $0.05 as of , it is 99.6% below that high and 0.0% above the low.
What is KPTI’s all-time high?
KPTI’s highest closing price was $706.80 on , adjusted for stock splits. At $0.05 as of , it is 100.0% below that record.
Has KPTI stock ever split?
Yes, once: 1-for-15 on .
How has KPTI stock performed?
Including dividends and measured to the last price on , KPTI has returned −99.4% so far this year and −99.1% over the past year, and −100.0% over five years (−79.3% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What exchange does KPTI trade on?
Karyopharm Therapeutics trades on the Nasdaq under the ticker symbol KPTI. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.